{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:06:27Z","timestamp":1785330387414,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Gemcitabine, oxaliplatin, and paclitaxel (GOP) therapy has shown antitumor activity as a conventional\u2010dose salvage regimen for relapsed or refractory germ cell tumors (GCTs) in European studies; however, data on Japanese patients remain limited. Therefore, we aimed to evaluate the real\u2010world efficacy and safety of GOP therapy in a multicenter Japanese cohort and explore outcomes according to platinum sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter study included 25 patients with relapsed or refractory GCTs treated with GOP between January 2012 and May 2025 at two institutions in Japan. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1, along with tumor marker evaluations. Progression\u2010free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 25 patients, 15 (60%) and 10 (40%) had platinum\u2010refractory disease and platinum\u2010non\u2010refractory disease, respectively. The median follow\u2010up was 14.4\u2009months. The overall response rate was 56%, with a complete response rate of 28%. The median PFS and OS were 6.9 and 23.1\u2009months, respectively. The estimated 2\u2010year OS and PFS rates were 48.7% and 36.0%, respectively. Survival outcomes were comparable between patients with platinum\u2010non\u2010refractory and platinum\u2010refractory diseases. Overall, 40% of patients survived for more than 2\u2009years after initiation of GOP therapy. Grades 3\u20134 hematologic toxicities were common but manageable, with no unexpected safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GOP therapy demonstrated clinically meaningful activity and acceptable tolerability in Japanese patients with relapsed or refractory GCTs, supporting GOP as a practical, conventional\u2010dose salvage option for platinum\u2010refractory diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70560","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:23:43Z","timestamp":1782937423000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Gemcitabine, Oxaliplatin, and Paclitaxel Salvage Chemotherapy in Japanese Patients With Relapsed or Refractory Germ Cell Tumors"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8719-8044","authenticated-orcid":false,"given":"Tomohiko","family":"Aigase","sequence":"first","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Kouno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sasaki Foundation Kyoundo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Nakaigawa","sequence":"additional","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kishida","sequence":"additional","affiliation":[{"name":"Department of Urology Kanagawa Cancer Center  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.10.007"},{"key":"e_1_2_12_3_1","unstructured":"European Association of Urology \u201cEAU Guidelines on Testicular Cancer \u201d2024 edition cited 2025 December 10 https:\/\/uroweb.org\/guidelines\/testicular\u2010cancer."},{"key":"e_1_2_12_4_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Clinical Practice Guidelines in Oncology: Testicular Cancer \u201dVersion 1. 2024 cited 2025 December 10 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf."},{"key":"e_1_2_12_5_1","unstructured":"Japanese Urological Association \u201cClinical Practice Guidelines for Testicular Tumors 2024 \u201d2024 cited 2025 December 10 https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/48_testicular_tumor.pdf."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.7.932"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2638"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.6678"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm526"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.019"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.11.007"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.26657\/gulhane.00040"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2022.07.880"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.4999\/uhod.204657"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh103"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.068"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.05.011"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0667-5"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067749"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1561"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.5395"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9401"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25162"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15648"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.01.025"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1760-x"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:31:56Z","timestamp":1785328316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/iju.70560"],"URL":"https:\/\/doi.org\/10.1111\/iju.70560","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70560"}}